AA3-DLin

AA3-DLin LNPs (0-64 µg/mL; 24 h) exhibit low cytotoxicity in differentiated C2C12 myotubes^[1].
The AA3-DLin-based LNP formulation (4 h) demonstrates efficient cellular uptake across LLC, B16F10, and 4T1 cancer cell lines, and this uptake is not altered by nebulization^[3].
The AA3-DLin-based LNP formulation (4-48 h) effectively mediates gene transfection and PD-L1 silencing in both murine and human lung cancer cell lines, and this efficacy is preserved after nebulization^[3].
The AA3-DLin-based LNP formulation (8-72 h) effectively delivers mscFv to LLC, B16F10, and 4T1 cells, leading to intracellular expression of anti-DDR1 scFv and its sustained secretion^[3].
AA3-Dlin LNPs (0.5-4 h) are efficiently internalized by HEK 293, HeLa, 4T1, and B16F10 cells in a time-dependent manner^[5].
AA3-Dlin LNPs (0.5 μg/mL; 4 h) facilitate endosomal escape to release mRNA into the cytosol of HEK 293, HeLa, 4T1, and B16F10 cells^[5].
The optimized A12 AA3-DLin LNP formulation (0.1 μg; 24 h) demonstrates superior in vitro mRNA transfection efficacy in Hek 293 cells compared to MC3 LNPs, lipofectamine 3000, and ALC-0315 LNPs, with no observed cytotoxicity^[6].
AA3-DLin LNPs (72 h) demonstrate excellent mRNA delivery efficiency and can be used for mRNA vaccine development and gene therapy research^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.